Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Fix loading of LeViT safetensor weights, remove conversion code which should have been deactivated Add 'SO150M' ViT weights trained with SBB recipes, decent results, but not optimal shape for ImageNet ...

Get the full experience! Unlock access to all videos with the Unlimited Trains.com Membership.